BCR::ABL1

About

Gene context: ABL1, BCR

Biomarker Type: Rearrangement

Present: True

Rearrangement Type: Fusion


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) BCR::ABL1, CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) BCR::ABL1, CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Blinatumomab